2,5-dichloro-4-(2-(methoxymethyl)piperidin-1-yl)pyrimidine | 1351762-07-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,5-dichloro-4-(2-(methoxymethyl)piperidin-1-yl)pyrimidine
• 英文别名: 2,5-Dichloro-4-[2-(methoxymethyl)piperidin-1-yl]pyrimidine
• CAS: 1351762-07-6
• 化学式: C₁₁H₁₅Cl₂N₃O
• 分子量: 276.166
• InChiKey: RARVTUOVTXOYAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS
  申请人：Baker-Glenn Charles

  公开号：US20110301141A1

  公开（公告）日：2011-12-08

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物的公式I：或其药用盐，其中m，n，X，R1，R2，R3，R5，R6和R7的定义如本文所述。还公开了制备这些化合物的方法以及将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。
• [EN] AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS<br/>[FR] DÉRIVÉS AMINOPYRIDINES EN TANT QUE MODULATEURS DE LRRK2
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013079493A1

  公开（公告）日：2013-06-06

  Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物的公式（I），或其药学上可接受的盐，其中m、n、X、R1、R2、R3、R4和R5的定义如本文所述。还公开了制备这些化合物的方法以及利用这些化合物治疗与LRRK2受体相关的疾病，例如帕金森病。
• AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
  申请人：Genentech, Inc.

  公开号：US20130157999A1

  公开（公告）日：2013-06-20

  Specific Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein m, X, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  公式I的特定化合物或其药学上可接受的盐，其中m，X，R1，R2，R3，R5，R6和R7的定义如本文所述。还揭示了制备这些化合物的方法，并使用这些化合物治疗与LRRK2受体相关的疾病，如帕金森病。
• COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
  申请人：Radeke Heike S.

  公开号：US20140328756A1

  公开（公告）日：2014-11-06

  The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

  本发明涉及用于合成和使用成像剂或其前体的系统、组合物和方法。使用本文所述的方法可以将成像剂前体转化为成像剂。在某些情况下，成像剂富含18F。在某些情况下，成像剂可以用于成像主体的感兴趣区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。在某些实施例中，提供了用于评估主体部分的灌注和神经支配不匹配的方法和组成物。
• 2-(PHENYL OR PYRID-3-YL) AMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3121174A1

  公开（公告）日：2017-01-25

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  式 I 的化合物： 或其药学上可接受的盐、 其中 m、n、X、R1、R2、R3、R4 和 R5 如本文所定义。还公开了制造这些化合物的方法和使用这些化合物治疗与 LRRK2 受体相关的疾病（如帕金森病）的方法。